AstraZeneca's China partner expects to be able to make 400 mln COVID-19 vaccine doses a year
BEIJING, Feb 2 (Reuters) - China's Shenzhen Kangtai Biological Products said on Tuesday it had completed a facility designed to be able to produce 400 million doses of AstraZeneca's COVID-19 vaccine per year, doubling a capacity target promised i...
Read more